Global Condom Market Size, Share, Trends, And Forecast, 2026-2033 Market To Reach USD 27.0 Billion At 9.0% CAGR As E-Commerce And Product Innovation Drive Growth
Dublin, Nov. 03, 2026 (GLOBE NEWSWIRE) -- "Condom Market Size, Share & Trends Analysis Report 2026-2033" has been added to ResearchAndMarkets.com's offering.
The global condom market was valued at USD 13.6 billion in 2025 and is projected to increase from USD 14.8 billion in 2026 to USD 27.0 billion by 2033. The market is expected to expand at a CAGR of 9.0% from 2026 to 2033, highlighting significant opportunities for manufacturers, distributors, public health organizations, retailers, and investors. Asia Pacific led the global market in 2025, accounting for 51.9% of total revenue.
The report provides global, regional, and country-level revenue analysis, market forecasts, and industry trend assessments across key sub-segments from 2021 to 2033. It evaluates the global condom market by material type, product, distribution channel, MEA distribution channel, and region. These insights support market assessment, competitive planning, product development, and long-term business strategy.
Market Segmentation by Material Type
- Latex Condoms Non-latex Condoms Polyurethane and Polyisoprene Lambskin Nitrile Butadiene Rubber (NBR)
Material type analysis provides revenue estimates and forecasts for 2021 - 2033, enabling stakeholders to evaluate demand across established and alternative condom materials. The segmentation also helps businesses assess product portfolios and identify areas with potential for future innovation.
Market Segmentation by Product
- Male Condoms Female Condoms
The product outlook examines revenue performance across male and female condoms from 2021 - 2033. This analysis offers insight into product-specific market opportunities and supports informed decisions related to manufacturing, commercialization, and market positioning.
Market Segmentation by Distribution Channel
- Public Health Distribution Drug Stores E-commerce Mass Merchandizers
The distribution channel assessment evaluates how condom products reach consumers through public health programs, retail outlets, online platforms, and large-scale merchants. For the MEA condom market, the report separately analyzes the Public Sector, Social Marketing, and Commercial Sector, with revenue forecasts covering 2021 - 2033.
Regional Condom Market Outlook
The report covers North America, Europe, Asia Pacific, Latin America, and MEA. Country-level analysis includes the U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Sweden, Denmark, Norway, Netherlands, Switzerland, Portugal, Japan, China, India, Australia, Thailand, South Korea, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait, Nigeria, Kenya, Zambia, Zimbabwe, Uganda, Egypt, Turkey, and Ghana.
With Asia Pacific holding more than half of global revenue in 2025, the region remains central to the market outlook. Coverage of mature and emerging economies allows organizations to compare regional performance, assess country-specific revenue potential, and identify priority markets for investment or expansion.
Strategic Value of the Report
- Comprehensive market analysis: Review revenue performance and forecasts across major materials, products, distribution channels, regions, and countries. Competitive landscape: Assess the market presence and strategic positioning of key industry participants. Future trends: Examine the principal trends and growth drivers influencing the global condom market through 2033. Actionable recommendations: Apply market intelligence to identify revenue opportunities and support strategic business decisions. Growth opportunity assessment: Evaluate market trends, segment potential, and geographic expansion prospects. Competition strategy: Use market share analysis and competitive insights to strengthen planning and positioning. Product innovation intelligence: Monitor relevant product developments and emerging opportunities within the industry.
The report offers a structured view of global condom market growth, supported by segment-level and regional revenue forecasts. Its coverage can help companies assess commercial opportunities, refine distribution strategies, evaluate competitive conditions, and prioritize investments in a market projected to reach USD 27.0 billion by 2033.
Key Topics Covered:
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Market Definitions
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. The internal database
1.5.3. Secondary Sources & Third-Party Perspectives
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Volume Price Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Material Type Outlook
2.2.2. Product Outlook
2.2.3. Distribution Channel Outlook
2.2.4. MEA Condom Market Distribution Channel Outlook
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing prevalence of HIV infections and STD
3.3.1.2. Favorable government initiatives
3.3.1.3. Increasing penetration of online retailers
3.3.2. Market Restraint Analysis
3.3.2.1. Social and cultural stigma in developing countries
3.3.2.2. Market entry barriers in African countries
3.3.3. Industry Opportunities
3.3.3.1. Technological advancements
3.3.4. Industry Challenges
3.3.4.1. Adverse effects from materials used in condoms
3.4. Business Environment Analysis
3.4.1. Industry Analysis - Porter's Five Forces Analysis
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.5. Average Regional Pricing Analysis of Different Variants of Condoms
3.6. Qualitative Analysis: Supply Chain Analysis of Condoms, Material Type
3.7. Estimated Profit Margin Analysis for Condom Manufacturing Companies, 2025
Chapter 4. Material Type Business Analysis
4.1. Condom Market: Material Type Movement Analysis
4.2. Condom Material Type Market: Segment Dashboard
4.3. Material Type Movement & Market Share Analysis, 2023 & 2033
4.4. Global Condom Market Estimates & Forecast, Material Type
4.5. Latex
4.5.1. Latex market, 2021 - 2033 (USD Million)
4.6. Non-Latex
4.6.1. Non-Latex market, 2021 - 2033 (USD Million)
4.6.2. Polyurethane Polyisoprene
4.6.2.1. Polyurethane polyisoprene market, 2021 - 2033 (USD Million)
4.6.3. Polyisoprene
4.6.3.1. Polyisoprene market, 2021 - 2033 (USD Million)
4.6.4. Lambskin
4.6.4.1. Lambskin market, 2021 - 2033 (USD Million)
4.6.5. Nitrile Butadiene Rubber (NBR)
4.6.5.1. Nitrile Butadiene Rubber (NBR) market, 2021 - 2033 (USD Million)
Chapter 5. Product Business Analysis
5.1. Condom Market: Product Movement Analysis
5.2. Condom Product Market: Segment Dashboard
5.3. Product Movement & Market Share Analysis, 2023 & 2033
5.4. Global Condom Market Estimates & Forecast, Product
5.5. Male Condom
5.5.1. Male condom market, 2021 - 2033 (USD Million)
5.6. Female Condom
5.6.1. Female condom market, 2021 - 2033 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Condom Market: Distribution Channel Movement Analysis
6.2. Condom Distribution Channel Market: Segment Dashboard
6.3. Distribution Channel Movement & Market Share Analysis, 2023 & 2033
6.4. Global Condom Market Estimates & Forecast, Distribution Channel
6.5. Public Health Distribution
6.5.1. Public health distribution market, 2021 - 2033 (USD Million)
6.6. Drug Stores
6.6.1. Drug stores market, 2021 - 2033 (USD Million)
6.7. E-commerce
6.7.1. E-commerce market, 2021 - 2033 (USD Million)
6.8. Mass Merchandizers
6.8.1. Mass Merchandizers market, 2021 - 2033 (USD Million)
Chapter 7. MEA Condom Market Distribution Channel Business Analysis
7.1. MEA Condom Market: Distribution Channel Movement Analysis
7.2. MEA Condom Distribution Channel Market: Segment Dashboard
7.3. Distribution Channel Movement & Market Share Analysis, 2023 & 2033
7.4. MEA Condom Market Estimates & Forecast, Distribution Channel
7.5. Public Sector
7.5.1. Public sector market, 2021 - 2033 (USD Million)
7.6. Social Marketing
7.6.1. Social marketing market, 2021 - 2033 (USD Million)
7.7. Commercial Sector
7.7.1. Commercial sector market, 2021 - 2033 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Regional Market Share Analysis, 2025 & 2033
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.5. North America
8.5.1. North America Condom Market, 2021 - 2033 (USD Billion)
8.5.2. U.S.
8.5.2.1. U.S. estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.5.2.2. Regulatory framework/scenario
8.5.2.3. Reimbursement scenario
8.5.2.4. Competitive scenario
8.5.2.5. U.S. Condom, 2021 - 2033 (USD million)
8.5.2.6. U.S. condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.5.3. Canada
8.5.3.1. Canada estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.5.3.2. Regulatory framework/scenario
8.5.3.3. Reimbursement scenario
8.5.3.4. Competitive scenario
8.5.3.5. Canada Condom, 2021 - 2033 (USD million)
8.5.3.6. Canada condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.5.4. Mexico
8.5.4.1. Mexico estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.5.4.2. Regulatory framework/scenario
8.5.4.3. Reimbursement scenario
8.5.4.4. Competitive scenario
8.5.4.5. Mexico condom market, 2021 - 2033 (USD million)
8.5.4.6. Mexico condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6. Europe
8.6.1. Europe Condom Market, 2021 - 2033 (USD Million)
8.6.2. UK
8.6.2.1. UK estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.2.2. Regulatory framework/scenario
8.6.2.3. Reimbursement scenario
8.6.2.4. Competitive scenario
8.6.2.5. UK condom market, 2021 - 2033 (USD million)
8.6.2.6. UK condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.3. Germany
8.6.3.1. Germany estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.3.2. Regulatory framework/scenario
8.6.3.3. Reimbursement scenario
8.6.3.4. Competitive scenario
8.6.3.5. Germany condom market, 2021 - 2033 (USD million)
8.6.3.6. Germany condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.4. France
8.6.4.1. France estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.4.2. Regulatory framework/scenario
8.6.4.3. Reimbursement scenario
8.6.4.4. Competitive scenario
8.6.4.5. France condom market, 2021 - 2033 (USD million)
8.6.4.6. France condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.5. Italy
8.6.5.1. Italy estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.5.2. Regulatory framework/scenario
8.6.5.3. Reimbursement scenario
8.6.5.4. Competitive scenario
8.6.5.5. Italy condom market, 2021 - 2033 (USD million)
8.6.5.6. Italy condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.6. Spain
8.6.6.1. Spain estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.6.2. Regulatory framework/scenario
8.6.6.3. Reimbursement scenario
8.6.6.4. Competitive scenario
8.6.6.5. Spain condom market, 2021 - 2033 (USD million)
8.6.6.6. Spain condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.7. Sweden
8.6.7.1. Sweden estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.7.2. Regulatory framework/scenario
8.6.7.3. Reimbursement scenario
8.6.7.4. Competitive scenario
8.6.7.5. Sweden condom market, 2021 - 2033 (USD million)
8.6.7.6. Sweden condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.8. Norway
8.6.8.1. Norway estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.8.2. Regulatory framework/scenario
8.6.8.3. Reimbursement scenario
8.6.8.4. Competitive scenario
8.6.8.5. Norway condom market, 2021 - 2033 (USD million)
8.6.8.6. Norway condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.9. Netherlands
8.6.9.1. Netherlands estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.9.2. Regulatory framework/scenario
8.6.9.3. Reimbursement scenario
8.6.9.4. Competitive scenario
8.6.9.5. Netherlands condom market, 2021 - 2033 (USD million)
8.6.9.6. Netherlands condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.10. Switzerland
8.6.10.1. Switzerland estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.10.2. Regulatory framework/scenario
8.6.10.3. Reimbursement scenario
8.6.10.4. Competitive scenario
8.6.10.5. Switzerland condom market, 2021 - 2033 (USD million)
8.6.10.6. Switzerland condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.11. Portugal
8.6.11.1. Portugal estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.11.2. Regulatory framework/scenario
8.6.11.3. Reimbursement scenario
8.6.11.4. Competitive scenario
8.6.11.5. Portugal condom market, 2021 - 2033 (USD million)
8.6.11.6. Portugal condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.6.12. Denmark
8.6.12.1. Denmark estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.6.12.2. Regulatory framework/scenario
8.6.12.3. Reimbursement scenario
8.6.12.4. Competitive scenario
8.6.12.5. Denmark condom market, 2021 - 2033 (USD million)
8.6.12.6. Denmark condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.7. Asia Pacific
8.7.1. Asia Pacific Condom Market, 2021 - 2033 (USD Billion)
8.7.2. Japan
8.7.2.1. Japan estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.7.2.2. Regulatory framework/scenario
8.7.2.3. Reimbursement scenario
8.7.2.4. Competitive scenario
8.7.2.5. Japan condom market, 2021 - 2033 (USD million)
8.7.2.6. Japan condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.7.3. China
8.7.3.1. China estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.7.3.2. Regulatory framework/scenario
8.7.3.3. Reimbursement scenario
8.7.3.4. Competitive scenario
8.7.3.5. China condom market, 2021 - 2033 (USD million)
8.7.3.6. China condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.7.4. India
8.7.4.1. India estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.7.4.2. Regulatory framework/scenario
8.7.4.3. Reimbursement scenario
8.7.4.4. Competitive scenario
8.7.4.5. India condom market, 2021 - 2033 (USD million)
8.7.4.6. India condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.7.5. Australia
8.7.5.1. Australia estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.7.5.2. Regulatory framework/scenario
8.7.5.3. Reimbursement scenario
8.7.5.4. Competitive scenario
8.7.5.5. Australia condom market, 2021 - 2033 (USD million)
8.7.5.6. Australia condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.7.6. Thailand
8.7.6.1. Thailand estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.7.6.2. Regulatory framework/scenario
8.7.6.3. Reimbursement scenario
8.7.6.4. Competitive scenario
8.7.6.5. Thailand condom market, 2021 - 2033 (USD million)
8.7.6.6. Thailand condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.7.7. South Korea
8.7.7.1. South Korea estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.7.7.2. Regulatory framework/scenario
8.7.7.3. Reimbursement scenario
8.7.7.4. Competitive scenario
8.7.7.5. South Korea condom market, 2021 - 2033 (USD million)
8.7.7.6. South Korea condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.8. Latin America
8.8.1. Latin America Condom Market, 2021 - 2033 (USD Billion)
8.8.2. Brazil
8.8.2.1. Brazil estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.8.2.2. Regulatory framework/scenario
8.8.2.3. Reimbursement scenario
8.8.2.4. Competitive scenario
8.8.2.5. Brazil condom market, 2021 - 2033 (USD million)
8.8.2.6. Brazil condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.8.3. Argentina
8.8.3.1. Argentina estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.8.3.2. Regulatory framework/scenario
8.8.3.3. Reimbursement scenario
8.8.3.4. Competitive scenario
8.8.3.5. Argentina condom market, 2021 - 2033 (USD million)
8.8.3.6. Argentina condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9. MEA
8.9.1. MEA Condom Market, 2021 - 2033 (USD Billion)
8.9.2. South Africa
8.9.2.1. South Africa estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.2.2. Regulatory framework/scenario
8.9.2.3. Reimbursement scenario
8.9.2.4. Competitive scenario
8.9.2.5. South Africa condom market, 2021 - 2033 (USD million)
8.9.2.6. South Africa condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.3. Saudi Arabia
8.9.3.1. Saudi Arabia estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.3.2. Regulatory framework/scenario
8.9.3.3. Reimbursement scenario
8.9.3.4. Competitive scenario
8.9.3.5. Saudi Arabia condom market, 2021 - 2033 (USD million)
8.9.3.6. Saudi Arabia condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.4. UAE
8.9.4.1. UAE estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.4.2. Regulatory framework/scenario
8.9.4.3. Reimbursement scenario
8.9.4.4. Competitive scenario
8.9.4.5. UAE condom market, 2021 - 2033 (USD million)
8.9.4.6. UAE condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.5. Kuwait
8.9.5.1. Kuwait estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.5.2. Regulatory framework/scenario
8.9.5.3. Reimbursement scenario
8.9.5.4. Competitive scenario
8.9.5.5. Kuwait condom market, 2021 - 2033 (USD million)
8.9.5.6. Kuwait condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.6. Nigeria
8.9.6.1. Nigeria estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.6.2. Regulatory framework/scenario
8.9.6.3. Reimbursement scenario
8.9.6.4. Competitive scenario
8.9.6.5. Nigeria condom market, 2021 - 2033 (USD million)
8.9.6.6. Nigeria condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.7. Kenya
8.9.7.1. Kenya estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.7.2. Regulatory framework/scenario
8.9.7.3. Reimbursement scenario
8.9.7.4. Competitive scenario
8.9.7.5. Kenya condom market, 2021 - 2033 (USD million)
8.9.7.6. Kenya condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.8. Zambia
8.9.8.1. Zambia estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.8.2. Regulatory framework/scenario
8.9.8.3. Reimbursement scenario
8.9.8.4. Competitive scenario
8.9.8.5. Zambia condom market, 2021 - 2033 (USD million)
8.9.8.6. Zambia condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.9. Zimbabwe
8.9.9.1. Zimbabwe estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.9.2. Regulatory framework/scenario
8.9.9.3. Reimbursement scenario
8.9.9.4. Competitive scenario
8.9.9.5. Zimbabwe condom market, 2021 - 2033 (USD million)
8.9.9.6. Zimbabwe condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.10. Uganda
8.9.10.1. Uganda estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.10.2. Regulatory framework/scenario
8.9.10.3. Reimbursement scenario
8.9.10.4. Competitive scenario
8.9.10.5. Uganda condom market, 2021 - 2033 (USD million)
8.9.10.6. Uganda condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.11. Egypt
8.9.11.1. Egypt estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.11.2. Regulatory framework/scenario
8.9.11.3. Reimbursement scenario
8.9.11.4. Competitive scenario
8.9.11.5. Egypt condom market, 2021 - 2033 (USD million)
8.9.11.6. Egypt condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.12. Turkey
8.9.12.1. Turkey estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.12.2. Regulatory framework/scenario
8.9.12.3. Reimbursement scenario
8.9.12.4. Competitive scenario
8.9.12.5. Turkey condom market, 2021 - 2033 (USD million)
8.9.12.6. Turkey condom market volume estimates and forecasts, 2021 - 2033 ('000)
8.9.13. Ghana
8.9.13.1. Ghana estimated prevalence of HIV/AIDs and STIs, 2021 - 2033 ('000)
8.9.13.2. Regulatory framework/scenario
8.9.13.3. Reimbursement scenario
8.9.13.4. Competitive scenario
8.9.13.5. Ghana condom market, 2021 - 2033 (USD million)
8.9.13.6. Ghana condom market volume estimates and forecasts, 2021 - 2033 ('000)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Company Market Position Analysis
9.3. Strategy Mapping
9.3.1. Expansion
9.3.2. Acquisition
9.3.3. Collaborations
9.3.4. Others
9.4. Company Profiles/Listing
9.4.1. FUJILATEX CO.,LTD
9.4.1.1. Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Reckitt
9.4.2.1. Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Church & Dwight Co., Inc.
9.4.3.1. Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Karex Berhad
9.4.4.1. Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. LELO iAB
9.4.5.1. Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Lifestyles
9.4.6.1. Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Okamoto Industries, Inc
9.4.7.1. Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. MAYER LABORATORIES, INC.
9.4.8.1. Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Cupid Limited
9.4.9.1. Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. RITEX GMBH
9.4.10.1. Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
9.4.11. Pasante Healthcare Ltd.
9.4.11.1. Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Strategic Initiatives
9.4.12. CPR GmbH
9.4.12.1. Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Strategic Initiatives
9.4.13. Mankind Pharma
9.4.13.1. Overview
9.4.13.2. Financial Performance
9.4.13.3. Product Benchmarking
9.4.13.4. Strategic Initiatives
9.4.14. Sagami Rubber Industries Co., Ltd.
9.4.14.1. Overview
9.4.14.2. Financial Performance
9.4.14.3. Product Benchmarking
9.4.14.4. Strategic Initiatives
9.4.15. rrtMedcon
9.4.15.1. Overview
9.4.15.2. Financial Performance
9.4.15.3. Product Benchmarking
9.4.15.4. Strategic Initiatives
List of Tables [119]
List of Figures [161]
Companies Featured
- FUJILATEX CO.,LTD Reckitt Church & Dwight Co., Inc. Karex Berhad LELO iAB Lifestyles Okamoto Industries, Inc MAYER LABORATORIES, INC. Cupid Limited RITEX GMBH Pasante Healthcare Ltd. (a subsidiary of Karex Berhad) CPR GmbH Mankind Pharma Sagami Rubber Industries Co., Ltd. rrtMedcon
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment